Sensyne Health announces strategic partnership with Microsoft and co-development of cloud and machine learning capabilities
Oxford, U.K. 28 October 2020: Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company” or the “Group”), the UK Clinical AI company, today announces that it has extended its existing association with Microsoft to become a ‘Strategic Partner’. The two companies will work together to further develop and refine Sensyne’s clinical AI and health cloud technologies to improve, augment, and reduce the cost of patient care.
The partnership is expected to deliver latest generation healthcare ‘cloud-first’ systems and cutting-edge predictive machine learning algorithms with the aim of reducing demand on global healthcare systems, while amplifying clinicians’ ability to deliver quality care at scale.
Highlights of the partnership include:
- Increasing Sensyne’s ability to create scalable and highly configurable healthcare technologies that are globally deployable and able to meet local, clinical and regulatory needs
- Sensyne will have early access to Microsoft tools enabling it to build new products with state -of-the-art features to enhance usability and cyber-security
- Broadens Sensyne’s sales channels around the world, promoting Sensyne’s products across Microsoft marketing channels while co-selling two of Sensyne’s products: SENDTM, a remote monitoring system for vital signs in hospitals, and GDm-HealthTM, a prescribed digital therapeutic for the management of diabetes during pregnancy at home
Sensyne will combine its expertise in remote monitoring, clinically led digital technologies and machine learning algorithms with Micosoft’s latest healthcare capabilities such as Health Cloud (clinical workflow and patient engagement tool), Virtual Consult (digital waiting room and remote consultation service), Healthcare Accelerator (pre-built healthcare entities that enable rapid compliance with industry standards), Health Bot (natural language interaction with patients and clinicians) and Azure IoMD (internet of things for clinical use).
Lord (Paul) Drayson PhD, CEO of Sensyne Health, said:
“This strategic partnership with Microsoft will further enhance Sensyne’s ability to advance and scale the benefits that advanced clinical AI can bring to improve patient outcomes and accelerate the development of new medicines through its research partnerships with NHS Trusts.”
Laura Robinson, Health and Life Sciences Lead, Microsoft Healthcare, said:
“Microsoft is focused on utilising the capabilities of AI and Machine Learning to enhance solutions across the healthcare sector. Sensyne Health shares our ambition to streamline and optimise operations in the sector and ultimately deliver better patient care.”